Yangzi State‑Owned Investment Group & Perennial Real Estate Join Forces to Build Jiangsu’s First Foreign‑Owned General Hospital
Hospital

Yangzi State‑Owned Investment Group & Perennial Real Estate Join Forces to Build Jiangsu’s First Foreign‑Owned General Hospital

Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina
CompanyDrug

Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina

TransThera Sciences and Neurocrine Biosciences Ink $881.5 M NLRP3 Collaboration
CompanyDeals

TransThera Sciences and Neurocrine Biosciences Ink $881.5 M NLRP3 Collaboration

Betta Pharma Secures Exclusive Greater‑China Rights to Gensciences’ Long‑Acting Factor VIII Therapy
CompanyDeals

Betta Pharma Secures Exclusive Greater‑China Rights to Gensciences’ Long‑Acting Factor VIII Therapy

AbbVie Posts 8.4% Revenue Gain in Q3 2025, EPS Slumps on IPR&D Charges
Company

AbbVie Posts 8.4% Revenue Gain in Q3 2025, EPS Slumps on IPR&D Charges

Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating‑Profit Surge in H1 FY2025
Company

Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating‑Profit Surge in H1 FY2025

FDA Issues Draft Guidance to Accelerate Biosimilar Development and Cut Costs
Policy / Regulatory

FDA Issues Draft Guidance to Accelerate Biosimilar Development and Cut Costs

Simnova’s DLL3‑Targeted CAR‑T (SNC115) Wins First‑In‑China Clinical‑Trial Approval for Relapsed SCLC
CompanyDrug

Simnova’s DLL3‑Targeted CAR‑T (SNC115) Wins First‑In‑China Clinical‑Trial Approval for Relapsed SCLC

Akeso’s ivonescimab (AK112) Receives Fourth Breakthrough Therapy Designation in China for Triple‑Negative Breast Cancer
CompanyDrug

Akeso’s ivonescimab (AK112) Receives Fourth Breakthrough Therapy Designation in China for Triple‑Negative Breast Cancer

CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China
CompanyDeals

CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China

FDA CDER Director George Tidmarsh Placed on Leave Amid Probe Over Drug‑Approval Program Concerns
Policy / Regulatory

FDA CDER Director George Tidmarsh Placed on Leave Amid Probe Over Drug‑Approval Program Concerns

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones
CompanyDeals

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones